Reduced morbidity and mortality in survivors of childhood acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study

By Dixon SB, Chen Y, Yasui Y, et al
Published October 8, 2020

Key Takeaways

To determine the impact of risk-stratified therapy for childhood acute lymphoblastic leukemia (ALL) on long-term toxicity, researchers undertook this study with 6,148 survivors of childhood ALL (median age, 27.9 years) diagnosed between 1970 and 1999. They formed 6 groups based on therapy combinations and treatment intensity: 1970s-like (70s), standard- or high-risk 1980s-like (80sSR, 80sHR) and 1990s-like (90sSR, 90sHR), and relapse/transplantation (R/BMT). They compared cumulative incidence, standardized mortality ratios, and standardized incidence ratios between treatment groups and with the US population. In this study, decreased late morbidity and mortality in correlation with risk-stratified therapy were reported among contemporary survivors of standard-risk ALL, represented by 90sSR. The observed health-related late mortality and subsequent malignant neoplasm risks in 5-year survivors of contemporary, standard-risk childhood ALL were shown to be comparable to the general population.

Read the full article on Journal of Clinical Oncology.

Share with emailShare to FacebookShare to LinkedInShare to Twitter